 |
|
|
|
|
Lobby
Day 2006Join us in Washington, D.C. on May 8-9 for the CFIDS Association of America's 14th Lobby Day on Capitol Hill. Be part of the group that spends the day talking with lawmakers and their staff members about funding for CFIDS research, care and treatment centers, disability and education issues.
Information about participation in a "virtual lobby day" for those who cannot make the trip but would like to add to the impact of Lobby Day is available by following the link below.
Registration Deadline: April 17!
When:
Sunday, April 30, 2006 from 9 a.m. to 4:30 p.m.
Where: Connecticut Convention Center, 100 Columbus
Boulevard, Hartford, CT.
Are you tired of living
with symptoms that don't seem to get better?
Would you like to learn more about how your body works?
Do you experience symptoms of headache, severe fatigue or brain
fog on a regular basis? Chronic pain or dizziness? Abdominal pain
or urinary frequency?
The conference will explore and define symptoms many of us live with daily.
Come and learn more about what causes your symptoms and treatment options - what works, what to avoid and cutting edge discoveries from our speakers."
Dr. Nancy Klimas, MD,
the highly respected international CFIDS researcher will be the
keynote speaker. Other speakers include an endocrinologist who
will speak on CFIDS and FM; a neuropsychologist who will speak
on cognitive dysfunction in CFIDS; a neurologist who will speak
on pain; a cardiologist who will speak on orthostatic intolerance;
a urologist who will speak on interstitial cystitis. There are
a number of other excellent presenters on important topics including
advocacy and
disability.
Increasing
number of fatal acute liver failure cases linked to the popular
painkiller Exciting
and Hopeful News for CFIDS Research and Treatment.
A New Research Approach - Genomics - Faulty Gene Expression in
CFIDS.
This special section
contains important updates on 3 research groups that have found
altered gene expression in CFIDS patients. Drs. Gow and Kerr in
England and the U.S. Centers for Disease Control have all found
similar alterations in cellular metabolism caused by abnormal
gene expression. The significance of this research is that it
may, in the future, lead to treatments and a better understading
of what actually causes the illness.
Kerr’s Team Finds Significant Differences in Gene Expression... |
New Jan. 2006
New for July 2005
A targeted Request for CFIDS Research Applications has just been issued. A promise had been made by NIH over two years ago to provide this special grant program for CFIDS research However it took sustained lobbying by patients and the CFIDS Association as well as some congressional intervention to move NIH. Read about this victory and its importance by clicking on this button.
New for June 2005
Dr. Benjamin Natelson, M.D., professor of neurosciences at the University of New Jersey Medical School, is a highly respected CFIDS researcher. He recently, using a new technology called proteomic profiling, has found abnormal proteins in the spinal fluid of CFIDS patients.
New for May 2005
February 22, 2005
At the International Conference on Fatigue Science held in Japan, several reports emerged discussing the role of a number of viruses, including HHV-6A, in the pathology of CFIDS. Presentations were made by renowned CFIDS specialists, like by Dr. Daniel Peterson and Dr. Dharam Ablashi, who found active HHV-6A virus in both the brain and spinal fluid of CFIDS patients. They report the virus is neurotrophic, that is, it invades nervous tissue. Dr. Peterson has been treating patients with two intravenous anti-viral drugs, including ampligen, and has found "the majority has responded."
Other scientists also present important findings. While there are no breakthroughs in the conference reports, the research may represent some substantial progress in understanding CFIDS.
New for March 2005
In a response to ongoing concerns about manufacturing quality, the Food and Drug Administration (FDA) and the Department of Justice today initiated seizures of Paxil CR and Avandamet tablets manufactured by GlaxoSmithKline, Inc. (GSK). Manufacturing practices for the two drugs, approved to treat depression and panic disorder (Paxil CR) and Type II Diabetes (Avandamet), failed to meet the standards laid out by FDA that ensure product safety, strength, quality and purity.
New for March 2005
International Conference on Chronic Fatigue Points to Low-grade Viral Infections in Brain
February 22, 2005 – The HHV-6 Foundation, an association formed to raise awareness, funding and further research for human herpesvirus 6 (HHV-6), has today announced that some cases of chronic fatigue syndrome (CFS) may be linked to human herpesvirus 6 A variant (HHV-6A). The announcement comes on the heels of the International Fatigue Conference on Fatigue Science that was held in Japan on February 9-11. The conference was attended by some 200 scientists from around the world.
New (2004), revised, comprehensive and updated
"How to Obtain Social Security Benefits if You Have Chronic Fatigue Syndrome (CFS/CFIDS)"
New for April 2003
The most accurate way yet developed to clinically determine if a person is likely to have CFIDS.
New for Dec. 2002
Please note that the Mass. CFIDS/FM Association does not endorse any specific medical hypothesis or treatment protocol.
Please send comments to:
Webmaster
Last Updated on: 03/12/2005
Copyright © MCMXCVII - ©
MMII Massachusetts CFIDS/FM Association
except where individual items are
otherwise copyrighted.
All rights
reserved.
